EFFECTS OF MEDICAL NUTRITIONAL TREATMENT ON POLYCYSTIC OVARIAN SYNDROME

Year 2019, Volume: 2 Issue: 1, 25 - 29, 09.07.2019

Özlem Özer Altundağ , Emre Batuhan Kenger Esma Nur Kılıç

Abstract

Polycystic ovary syndrome
(PCOS) is the most common endocrine disorder seen in women, and although it
affects 10% of reproductive age women, it is often overlooked in the clinic. The
aim of this study was to investigate the effects of medical nutrition therapy
on PCOS patients. This study was
conducted with the aim of investigating and investigating the effects of
medical nutrition therapy on PCOS patients. The study was conducted on
polycystic over and medical nutrition therapy; 27 articles published between
2001 and 2018 were scanned. Higher
body mass index (BMI), obesity and insulin resistance may play an important
role in the pathogenesis of depression in women with PCOS and weight m In addition, chromium, iron, selenium and
vitamin D supplements are reported to affect the disease positively. 50% to 70% of women with PCOS are obese,
and 5% to 10% weight loss in patients is reported to be associated with
significant improvements in metabolic and hormonal markers. In the studies, it
was reported that exercise and diet provided additional benefit and PCOS
patients were reported to have positive effects on the course of the disease by
positively affecting the state of inflammation by feeding with rich resources
and omega-3 rich foods management is effective in relieving symptoms. It has been reported that weight loss and lifestyle
changes in PCOS support treatment and decrease the complications and increase
the quality of life of individuals. Nutritional
therapy should be planned individually and supported by further research in
PCOS patients such as many diseases.

Keywords

Polycystic Over, Medical Nutrition Therapy, Diet

References

• [1] Stein, I. F. & Leventhal, M. L. Amenorrhea associated with bilateral polycystic ovaries (1935). Am. J. Obstet. Gynecol. 29, 181–191.[2] World Health Organization (1992). The ICD10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. (World Health Organization, Geneva)[3] Escobar-Morreale,H.F (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.Nature,24(14),270-284.[4] Jalilian A, Kiani F, Sayehmiri F, Sayehmiri K, Khodaee Z, Akbari M (2015). Prevalence of polycystic ovary syndrome and its associated complications in Iranian women: a meta-analysis. Iran J Reprod Med;13(10),591–604.[5] Moran LJ, Brinkworth GD, Norman RJ (2008).Dietary therapy in polycystic ovary syndrome. Semin Reprod Med,26(1),85–92.[6] Copp T, Jansen J, Doust J, WJ Mol B, Dokras A, McCaffery K (2017). Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome?.The BMJ,358(10),1-10.[7] Faghfooria Z, Fazelianb S, Shadnoushc M, Goodarzid R (2017), Nutritional management in women with polycystic ovary syndrome: A review study. Diabetes & Metabolic Syndrome: Clinical Research &Reviews,11,429-432.[8] Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ (2003). Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab,88(2),812–9.[9] Douglas CC, Gower BA, Darnell BE, Ovalle F, Oster RA, Azziz R (2006). Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril,85(3),679–88.[10] Kasim-Karakas SE, Almario RU, Gregory L, Wong R, Todd H, Lasley BL (2004).Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome. J Clin Endocrinol Metab,89(2),615–20.[11] Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS (2004). A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril,81(3),630–7.[12] Escobar-Morreale, H.F. and Luque-Ramirez, M. (2011) Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome. Fertil. Steril. 95,1730–1735.[13] Alvarez-Blasco, F. et al. (2009) Role of haptoglobin in polycystic ovary syndrome (PCOS), obesity and disorders of glucose tolerance in premenopausal women. PLoS ONE 5(4),2-7.[14] Swaminathan, S. et al. (2007). The role of iron in diabetes and its complications. Diabetes Care,30, 1926–1933.[15] Martinez-Garcia, M.A. et al (2009). Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance and genomic variants related to inflammation, oxidative stress and iron metabolism. Diabetes Care 32, 1525–1530.[16] Freeman D, Norrie J, Sattar N (2001). The determinants of diabetes in the WOSCOPS cohort study. Circulation,103(3),57–62.[17] Wu R, Fujii S, Ryan NK, Van der Hoek KH (2007). Ovarian leukocyte distribution and cytokine/chemokine mRNA expression in follicular fluid cells in women with polycystic ovary syndrome. Hum Reprod,22(5),27–35.[18] Xionga Y, LiangbXing X, Weib Y (2011). Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology,159(1),148-150.[19] Khani B, Mardanian F, Fesharaki SJ (2017). Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome. J Res Med Sci,22,64-69. [20] Sekhon LH, Gupta S, Kim Y, Agarwal A (2010). Female infertility and antioxidants. Curr Womens Health Rev,6,84–95.[21] Yang K, Zeng L, Bao T (2018). Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive Biology and Endocrinology,27(16),2-13.[22] Wehr E, Pilz S, Schweighofer N, et al(2009).Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol,161(5),75-82.[23] Hahn S, Haselhorst U, Tan S, et al (2006).Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes,114(5),57-83.[24] Yildizhan R, Kurdoglu M, Adali E et al (2009). Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet,280(5),59-63.[25] Norman RJ, Dewailly D, Legro RS, et al(2007). Polycystic ovary syndrome. Lancet,370(6),85-97.[26] Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK (2011).Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome.Metabolism, 60(10),1475-81.[27] Wright C, Zborowski1 J, Talbott E, McHugh-Pemu1 K, Youk A (2004). Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. International Journal of Obesity, 28, 1026–1032.